Mouse stem cell line with a disrupted lck gene. Mus musculus (CRL-2542)

Designation / Description Mouse stem cell line with a disrupted lck gene. Mus musculus
U.S. Patent Number
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Comments
The replacement-type vector (PmlckBSNeo2.3) was introduced into D3 embryonic stem (ES) cells by electroporation to disrupt the lck locus.
Two cell lines, 59B5 (ATCC-CRL-11115) and 56B3 (ATCC-CRL-11117), were generated that were deficient for the lck gene.
These cell lines were used to produce mutant mice with germ line transmission for lck disruption.
Heterozygous mice were inbred to obtain mice homozygous for the disrupted lck gene.
A culture submitted to the ATCC as CRL-11117 in September of 1992 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cured cell line is available as CRL-2542. The original patent deposit is available as CRL-11117.
The line should be grown on feeder layers of mitomycin C treated (0.01 mg/ml for 90 minutes) primary mouse embryonic fibroblasts or STO cells (see ATCC CRL-1503 or ATCC 56-X.2, MITC-STO cells).
Shipped frozen
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Mak TW. Mouse having a disrupted lck gene. US Patent 5,625,122 dated Apr 29 1997